Renowned neuromuscular clinician and researcher to shape care strategies and support global Duchenne community

CureDuchenne has appointed Brenda Wong, MD, as Chief Medical Advisor. A leading figure in neuromuscular medicine and a long-time advocate for patient-centered care, Dr Wong will guide the organization’s clinical strategy, support families, and advise on trial design across its research and industry collaborations.

“I am very excited to join CureDuchenne for the next chapter of my advocacy, advancing clinical care and research for our Duchenne and Becker muscular dystrophy community.”

Dr Wong

Dr Wong has spent more than two decades advancing care for individuals living with Duchenne and Becker muscular dystrophy. She previously directed the Comprehensive Neuromuscular Center at Cincinnati Children’s Hospital Medical Center, before founding the Duchenne Muscular Dystrophy Center at the University of Massachusetts Memorial Medical Center. She also holds academic appointments at the University of Massachusetts Chan Medical School.

At CureDuchenne, she will work across medical, research, and patient engagement functions, contributing to the development of improved standards of care and ensuring programs reflect the evolving needs of the community. She will also provide strategic insight to pharmaceutical and biotech partners on clinical trial design, with a focus on scientific rigor and patient inclusion.

“I look forward to helping accelerate the development and accessibility of transformative therapies, while supporting families and individuals through every stage of their journey.”

Dr Wong shared her expertise at CureDuchenne’s upcoming FUTURES National Conference in San Antonio, where she lead sessions addressing medical care for Duchenne and Becker muscular dystrophy, including clinical trial navigation, female dystrophinopathy, and daily life challenges faced by patients and caregivers.